These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

699 related items for PubMed ID: 19073834

  • 1. CSF APPs alpha and phosphorylated tau protein levels in mild cognitive impairment and dementia of Alzheimer's type.
    Fellgiebel A, Kojro E, Müller MJ, Scheurich A, Schmidt LG, Fahrenholz F.
    J Geriatr Psychiatry Neurol; 2009 Mar; 22(1):3-9. PubMed ID: 19073834
    [Abstract] [Full Text] [Related]

  • 2. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.
    Neurology; 2009 Mar 24; 72(12):1056-61. PubMed ID: 19307538
    [Abstract] [Full Text] [Related]

  • 3. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
    Maccioni RB, Lavados M, Guillón M, Mujica C, Bosch R, Farías G, Fuentes P.
    Neurobiol Aging; 2006 Feb 24; 27(2):237-44. PubMed ID: 16399209
    [Abstract] [Full Text] [Related]

  • 4. CSF markers in Alzheimer disease patients are not related to the different degree of cognitive impairment.
    Stefani A, Martorana A, Bernardini S, Panella M, Mercati F, Orlacchio A, Pierantozzi M.
    J Neurol Sci; 2006 Dec 21; 251(1-2):124-8. PubMed ID: 17097109
    [Abstract] [Full Text] [Related]

  • 5. Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.
    Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.
    Mech Ageing Dev; 2006 Feb 21; 127(2):129-32. PubMed ID: 16274728
    [Abstract] [Full Text] [Related]

  • 6. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study.
    Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Bürger K, Hampel H, Frölich L, Wolf S, Prinz B, Jahn H, Luckhaus Ch, Perneczky R, Hüll M, Schröder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kölsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J.
    Mol Psychiatry; 2010 Feb 21; 15(2):138-45. PubMed ID: 18663368
    [Abstract] [Full Text] [Related]

  • 7. Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment.
    Zhong Z, Ewers M, Teipel S, Bürger K, Wallin A, Blennow K, He P, McAllister C, Hampel H, Shen Y.
    Arch Gen Psychiatry; 2007 Jun 21; 64(6):718-26. PubMed ID: 17548753
    [Abstract] [Full Text] [Related]

  • 8. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
    Sundelöf J, Sundström J, Hansson O, Eriksdotter-Jönhagen M, Giedraitis V, Larsson A, Degerman-Gunnarsson M, Ingelsson M, Minthon L, Blennow K, Kilander L, Basun H, Lannfelt L.
    J Alzheimers Dis; 2010 Jun 21; 21(2):471-8. PubMed ID: 20555147
    [Abstract] [Full Text] [Related]

  • 9. False recognition correlates with amyloid-beta (1-42) but not with total tau in cerebrospinal fluid of patients with dementia and mild cognitive impairment.
    Hildebrandt H, Haldenwanger A, Eling P.
    J Alzheimers Dis; 2009 Jun 21; 16(1):157-65. PubMed ID: 19158431
    [Abstract] [Full Text] [Related]

  • 10. CSF phosphorylated tau protein and mild cognitive impairment: a prospective study.
    Arai H, Ishiguro K, Ohno H, Moriyama M, Itoh N, Okamura N, Matsui T, Morikawa Y, Horikawa E, Kohno H, Sasaki H, Imahori K.
    Exp Neurol; 2000 Nov 21; 166(1):201-3. PubMed ID: 11031097
    [Abstract] [Full Text] [Related]

  • 11. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology.
    Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R.
    J Alzheimers Dis; 2010 Nov 21; 20(1):253-60. PubMed ID: 20164582
    [Abstract] [Full Text] [Related]

  • 12. Meta-analysis of CSF and MRI biomarkers for detecting preclinical Alzheimer's disease.
    Schmand B, Huizenga HM, van Gool WA.
    Psychol Med; 2010 Jan 21; 40(1):135-45. PubMed ID: 19863841
    [Abstract] [Full Text] [Related]

  • 13. Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults.
    Stomrud E, Hansson O, Zetterberg H, Blennow K, Minthon L, Londos E.
    Arch Neurol; 2010 Feb 21; 67(2):217-23. PubMed ID: 20142530
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
    Ewers M, Zhong Z, Bürger K, Wallin A, Blennow K, Teipel SJ, Shen Y, Hampel H.
    Brain; 2008 May 21; 131(Pt 5):1252-8. PubMed ID: 18334538
    [Abstract] [Full Text] [Related]

  • 16. Cerebrospinal fluid TAU protein and amyloid beta42 in mild cognitive impairment: prediction of progression to Alzheimer's disease and correlation with the neuropsychological examination.
    Ivanoiu A, Sindic CJ.
    Neurocase; 2005 Feb 21; 11(1):32-9. PubMed ID: 15804922
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study.
    Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P.
    Neurobiol Aging; 2010 May 21; 31(5):758-64. PubMed ID: 18692273
    [Abstract] [Full Text] [Related]

  • 20. Increased total TAU but not amyloid-beta(42) in cerebrospinal fluid correlates with short-term memory impairment in Alzheimer's disease.
    Lin YT, Cheng JT, Yao YC, Juo, Lo YK, Lin CH, Ger LP, Lu PJ.
    J Alzheimers Dis; 2009 May 21; 18(4):907-18. PubMed ID: 19749420
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.